Giovanni Rezza

Giovanni Rezza

Auto-generated profile, based on publicly available information

Giovanni Rezza

G. Rezza, M. Dorrucci, P. Pezzotti (Centro Operativo AIDS), P. Monini, B. Ensoli (Laboratory of Virology), Istituto Superiore di Sanità, Rome, Italy

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
GRGiovanni Rezza
Giovanni Rezza
MAMassimo Andreoni
Massimo Andreoni
MDMaria Dorrucci
Maria Dorrucci
PPPatrizio Pezzotti
Patrizio Pezzotti
PMPaolo Monini
Paolo Monini
Barbara EnsoliBarbara Ensoli
Barbara Ensoli
BACKGROUND: The incidence of Kaposi's sarcoma (KS) is increased severalfold in individuals infected with human immunodeficiency virus-1 (HIV). Human herpesvirus 8 (HHV8) has also been implicated in KS. We investigated several factors that may determine the onset of KS, particularly HHV8 infection in individuals after becoming seropositive for HIV. METHODS: We studied 366 individuals belonging to different HIV-exposure categories (i.e., homosexual activity, intravenous drug use, and heterosexual contact) for whom a negative HIV serologic test and then a positive HIV serologic test were available within a 2-year period. HHV8 antibody testing was performed by use of an immunofluorescence assay on the first serum sample available after the first positive HIV test. Actuarial rates of progression of KS and of other acquired immunodeficiency syndrome (AIDS)-defining diseases were estimated by use of time-to-event statistical methods. All statistical tests were two-sided. RESULTS: Twenty-one of the 366 study participants developed AIDS-related KS, and 83 developed AIDS without KS. One hundred forty (38.3%) participants had detectable anti-HHV8 antibodies. The actuarial progression rate to KS among persons co-infected with HIV/HHV8 was nearly 30% by 10 years after HIV seroconversion. Increasing HHV8 antibody titers increased the risk of developing KS (for seronegative versus highest titer [1 : 125 serum dilution], adjusted relative hazard [RH] = 51.82; 95% confidence interval [CI] = 6.08-441.33) but not of other AIDS-defining diseases (adjusted RH = 1.14; 95% CI = 0.72-1.80). HHV8-seropositive homosexual men compared with HHV8-seropositive participants from other HIV-exposure categories showed an increased risk of KS that approached statistical significance (adjusted RH = 6.93; 95% CI = 0.88-54.84). CONCLUSIONS: Approximately one third of individuals co-infected with HIV/HHV8 developed KS within 10 years after HIV seroconversion. Progression to KS increased with time after HIV seroconversion. Higher antibody titers to HHV8 appear to be related to faster progression to KS but not to other AIDS-defining diseases.

29 July 1998 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
GRGiovanni Rezza
Giovanni Rezza
ELEvelyne T. Lennette
Evelyne T. Lennette
Massimo GiulianiMassimo Giuliani
Massimo Giuliani
PPPatrizio Pezzotti
Patrizio Pezzotti
FCFederico Caprilli
Federico Caprilli
Barbara EnsoliBarbara Ensoli
Barbara Ensoli
Three hundred seventy‐nine individuals [137 non‐injecting drug using (non‐IDU) heterosexuals, 130 homosexual men and 112 IDU] attending the human immunodeficiency virus (HIV) testing program of a sexually transmitted disease (STD) clinic in Rome were studied to estimate the prevalence and to identify the modalities of transmission of human herpesvirus‐8 (HHV‐8) infection. Serological analysis was performed by using an immunofluorescence assay able to detect anti‐latent and anti‐lytic HHV‐8 antibodies. Twelve acquired immunodeficiency syndrome (AIDS)‐Kaposi's sarcoma (KS) patients and 94 blood donors were tested as reference population groups. Anti‐lytic antibodies were detected in 185 (48.8%) individuals; 52 of them (13.7%) also had anti‐latent antibodies. Both anti‐lytic and anti‐latent antibody prevalence were higher among homosexual men (66.9% and 27.7%, respectively) than among IDU (49.1% and 8.0%, respectively) and non‐IDU heterosexuals (31.4% and 5.1%, respectively), and tended to increase with age. Anti‐lytic HHV‐8 antibodies were associated with syphilis [odds ratio (OR) = 3.81] but not with hepatitis C virus (HCV) seropositivity. HIV‐infected homosexual men were more likely to have HHV‐8 antibodies than those who were HIV‐negative. When using anti‐latent antibodies the direction of the OR remained the same, although the associations did not often reach statistical significance. Among AIDS‐KS patients, 83.3% had anti‐lytic and 66.6% had anti‐latent antibodies. Among blood donors, 28% had anti‐lytic antibodies and 2 of them (2.1%) also had anti‐latent antibodies. Our data indicate that HHV‐8 seroprevalence increases with age and is higher among homosexual men, particularly those infected with HIV. This is consistent with sexual transmission of HHV‐8 infection. In addition, the presence of HHV‐8 antibodies in HIV‐negative non‐IDU heterosexual contacts and in healthy blood donors is consistent with the high incidence of classic KS in Italy. Int. J. Cancer. 77:361–365, 1998.

1 April 2001 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
PPPatrizio Pezzotti
Patrizio Pezzotti
MPMarilena Pappagallo
Marilena Pappagallo
APAndrew N. Phillips
Andrew N. Phillips
SBStefano Boros
Stefano Boros
CVCatia Valdarchi
Catia Valdarchi
GRGiovanni Rezza
Giovanni Rezza

1 July 1987 in Nature
Verified
Journal Article
Closed access
PDF file
GLGiuseppe Luzi
Giuseppe Luzi
FAFernando Aiuti
Fernando Aiuti
GRGiovanni Rezza
Giovanni Rezza
DGDonato Greco
Donato Greco